Lacosamide
Other Antiepileptics
Sold as VIMPAT · TRELEMA TREATMENT…
- Drug class
- Other Antiepileptics
- Availability
- Prescription only
- Routes
- Oral, Intravenous
- Markets covered
- 4
- Products on record
- 289
- FDA reports (12 mo)
- 2,521
Overview
Plain-language summary, compiled from the cited regulatory records
Lacosamide is an active ingredient classified as an other antiepileptic [1]. It is approved for the treatment of partial-onset seizures in patients aged 4 years and older [1]. Additionally, it is indicated for use as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients aged 4 years and older [1].
In the past 12 months, there have been 2,521 adverse event reports associated with lacosamide [2]. The most frequently reported reactions include seizures, ineffective drug response, off-label use, somnolence, and issues related to product dose omission [2]. Lacosamide is available under various brand names in this market.
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| GB United Kingdom | MHRA | 209 | May 22, 2026 |
| CA Canada | Health Canada | 63 | May 5, 2026 |
| US United States | FDA | 13 | May 7, 2026 |
| EU European Union | EMA | 4 | March 11, 2026 |
GBUnited Kingdom· MHRA
209 products
Uses
Lacosamide Glenmark is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. Lacosamide Glenmark is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
How to take
CACanada· Health Canada
63 products
Uses
VIMPAT (lacosamide) is indicated as: Monotherapy in the management of partial-onset seizures in adult (>18 years of age) patients with epilepsy. All patients who participated in the monotherapy trial were newly or recently diagnosed with epilepsy (see 14 CLINICAL TRIALS).
Adjunctive therapy in the management of partial-onset seizures in adult patients with epilepsy who are not satisfactorily controlled with conventional therapy. 3 Pediatrics). 2 Geriatrics Geriatrics (>65 years of age): The clinical experience with VIMPAT in elderly patients with epilepsy is limited.
3 Pharmacokinetics, Special Populations and Conditions, Geriatrics).
How to take
USUnited States· FDA
13 products
Uses
1 Partial-Onset Seizures Lacosamide injection is indicated for the treatment of partial-onset seizures in patients 4 years of age and older. 's VIMPAT® (lacosamide) injection. 's marketing exclusivity rights, this drug product is not labeled with that information.
2 Primary Generalized Tonic-Clonic Seizures Lacosamide is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older.
How to take
EUEuropean Union· EMA
4 products
Uses
Vimpat is indicated as monotherapy in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy. Vimpat is indicated as adjunctive therapy • in the treatment of partial-onset seizures with or without secondary generalisation in adults, adolescents and children from 2 years of age with epilepsy.
• in the treatment of primary generalised tonic-clonic seizures in adults, adolescents and children from 4 years of age with idiopathic generalised epilepsy.
How to take
Drug interactions
Known interactions involving Lacosamide. Select one for details. This list is informational and not a complete interaction checker.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]MHRA (UK) · PL252580326 · revised September 6, 2024
- [2]Health Canada (DPD) · 02357615 · revised March 22, 2025
- [3]FDA DailyMed · 00203a7b-e774-45… · revised October 16, 2024 [PDF]
- [4]European Medicines Agency · EMEA/H/C/000863 · revised March 11, 2026
- [5]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.